Tri Locum Partners LP Decreases Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Tri Locum Partners LP significantly reduced its holdings in Teva Pharmaceutical Industries by selling 1,362,108 shares, leading to a 56.2% decrease in its position.
• Several other hedge funds, including Dimensional Fund Advisors LP and Price T Rowe Associates, increased their positions in Teva Pharmaceutical Industries during the 4th quarter, indicating a shift in institutional investor interest.
• Teva recently reported earnings with an EPS of $0.66, surpassing analyst expectations, and set a guidance for FY 2025 EPS between 2.500-2.600.

Tri Locum Partners LP lessened its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 56.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,061,008 shares of the company's stock after selling 1,362,108 shares during the period. Teva Pharmaceutical Industries comprises about 8.4% of Tri Locum Partners LP's holdings, making the stock its 4th largest holding. Tri Locum Partners LP owned approximately 0.09% of Teva Pharmaceutical Industries worth $16,308,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of TEVA. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 197,885.2% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company's stock valued at $338,989,000 after acquiring an additional 22,044,407 shares during the last quarter. Duquesne Family Office LLC lifted its stake in shares of Teva Pharmaceutical Industries by 530.1% in the 4th quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company's stock valued at $198,303,000 after acquiring an additional 7,569,450 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of Teva Pharmaceutical Industries by 472.8% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 6,283,688 shares of the company's stock valued at $96,078,000 after acquiring an additional 5,186,592 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Teva Pharmaceutical Industries by 416.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 5,983,928 shares of the company's stock valued at $91,973,000 after acquiring an additional 4,824,247 shares during the last quarter. Finally, Nuveen LLC bought a new position in Teva Pharmaceutical Industries during the 1st quarter valued at approximately $40,827,000. Institutional investors own 54.05% of the company's stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, insider Placid Jover sold 6,053 shares of the firm's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $91,763.48. Following the transaction, the insider directly owned 6,774 shares in the company, valued at $102,693.84. This trade represents a 47.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Matthew Shields sold 6,206 shares of the firm's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the transaction, the executive vice president directly owned 9,989 shares in the company, valued at approximately $170,012.78. This represents a 38.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 65,001 shares of company stock worth $996,958. Insiders own 0.49% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. The Goldman Sachs Group assumed coverage on Teva Pharmaceutical Industries in a research report on Friday, June 6th. They set a "buy" rating and a $24.00 price target for the company. Truist Financial assumed coverage on Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They set a "buy" rating and a $25.00 price target for the company. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. UBS Group lowered their price target on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. Finally, Bank of America upped their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Two analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $24.71.

Teva Pharmaceutical Industries Stock Up 2.0%

Shares of NYSE:TEVA traded up $0.37 during trading on Friday, hitting $18.41. The stock had a trading volume of 7,153,308 shares, compared to its average volume of 11,201,270. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $22.80. The company has a market capitalization of $21.11 billion, a PE ratio of -115.04, a PEG ratio of 1.09 and a beta of 0.62. The firm's fifty day moving average is $16.86 and its 200 day moving average is $16.32. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.02. The company had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The firm's quarterly revenue was up .3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.